Awareness of, usage of and willingness to use HIV pre-exposure prophylaxis among men in downtown Toronto, Canada

International Journal of STD and AIDS

Volumn 22, Issue 12, 2011, Pages 738-741

  Leonardi, M ^a   Lee, E ^a   Tan, D H S ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b Hassle Free Clinic   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Canada; HIV; Men who have sex with men; MSM; Pre exposure prophylaxis; PrEP; Sexual behaviour

Indexed keywords

ADULT; ARTICLE; AWARENESS; CANADA; HEALTH CENTER; HETEROSEXUAL MALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SEXUAL BEHAVIOR; SEXUAL HEALTH; SEXUALITY; SUBSTANCE ABUSE;

ADULT; ANTI-HIV AGENTS; ANTIBIOTIC PROPHYLAXIS; COHORT STUDIES; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ONTARIO; QUESTIONNAIRES; SEXUAL BEHAVIOR;

EID: 83455162552     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2011.011057     Document Type: Article

References (21)

1. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009;48:806-15
2. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a Phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trial 2007;2:e27.
3. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99.
4. Costello D. AIDS pill as a party drug? The Los Angeles Times, 19 December 2005.
5. Weinstein S. Safer or Stupid? Some Gay Men 'PrEP' for Sex. EDGE. 10 March 2009
6. Weinstein S. The Next Condom Conundrum. The Advocate, February 2009: 77-79
7. Voetsch AC, Heffelfinger JD, Begley EB, et al. Knowledge and use of preexposure and postexposure prophylaxis among attendees of minority gay pride events, 2005 through 2006. J Acquir Immune Defic Syndr 2007;46:378-80
8. Mimiaga MJ, Case P, Johnson CV, et al. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr 2009;50:77-83
9. Liu AY, Kittredge PV, Vittinghoff E, et al. Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr 2008;47:241-47
10. Grohskopf L, Gvetadze R, Pathak S, et al. Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among U.S. men who have sex with men (MSM). Paper presented at 18th International AIDS Conference, Vienna, Austria, July 2010. Abstract no. FRLBC102
11. Liu AY, Grant RM, Buchbinder SP. Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA 2006;296:863-65
12. Chesney M, Chambers D, Kahn J. Risk behavior for infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immun Defic Syndr Hum Retrovirol 1997;16:266-71
13. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr 2010;54:548-55
14. Cassell MM, Halperin DT, Shelton JD, Stanton D. Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ 2006;332:605-07
15. Bartholow BN, Buchbinder S, Celum C, et al. HIV sexual risk behaviour over 36 months of follow-up in the world's first HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2005;39:90-101
16. Guest G, Shattuck D, Johnson L, et al. Changes in sexual risk behaviour among participants in a PREP HIV prevention trial. Sex Transm Dis 2008;35:1002-08
17. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51:496-505
18. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:1273-81
19. Mulligan K, Glidden D, Gonzalez P, et al. Effects of FTC/TDF on bone mineral density in seronegative men from 4 continents: DEXA results of the global iPrEx study. Paper presented at 18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011; Boston, MA. Abstract 94LB
20. Liu A, Vittinghoff E, Irby R, et al. BMD loss in HIV- men participating in a TDF PrEP clinical trial in San Francisco. Paper presented at 18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011; Boston, MA. Abstract 93
21. Honkoop P, de Man RA, Niesters HG, et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-39